Cost–Utility Analysis of PCSK9 Inhibitors and Quality of Life: A Two-Year Multicenter Non-Randomized Study

Cost–Utility Analysis of PCSK9 Inhibitors and Quality of Life: A Two-Year Multicenter Non-Randomized Study

The primary objective of this study was to conduct a cost–utility analysis of proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors in real-world, comparing their use with standard care for managing cardiovascular disease. A multicenter prospective study was conducted across 12 Spanish ho...

Full description

Saved in:
Bibliographic Details
Main Authors: José Seijas-Amigo, Maria José Mauriz-Montero, Pedro Suarez-Artime, Mónica Gayoso-Rey, Francisco Reyes-Santías, Ana Estany-Gestal, Antonia Casas-Martínez, Lara González-Freire, Ana Rodriguez-Vazquez, Natalia Pérez-Rodriguez, Laura Villaverde-Piñeiro, Concepción Castro-Rubinos, Esther Espino-Paisán, Octavio Cordova-Arevalo, Diego Rodriguez-Penas, Begoña Cardeso-Paredes, Marta Ribeiro-Ferreiro, Moisés Rodríguez-Mañero, Alberto Cordero, José R. González-Juanatey, MEMOGAL Investigators
Format: Article
Language:English
Published: MDPI AG 2024-10-01
Series:Diseases
Subjects:
PCSK9 inhibitors
cost–utility analysis
quality of life
real-world study
cardiovascular disease
Online Access:https://www.mdpi.com/2079-9721/12/10/244
Tags: Add Tag
No Tags, Be the first to tag this record!

Internet

https://www.mdpi.com/2079-9721/12/10/244

Similar Items